Evaluation of photodynamic therapy (a treatment that involves light-sensitive medicine and a light source to destroy abnormal cells) as a safe and effective treatment for malaria

Evaluation of anti-microbial photodynamic therapy (using riboflavin as sensitizer) as a safe and effective treatment option for malaria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN80135736

Enrollment

200

Registered

2022-09-06

Start date

2020-11-01

Completion date

Unknown

Last updated

2022-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria (p. falciparum) Infections and Infestations

Interventions

Comparison between treatment and control group, both composed of patients suffering from Malaria (p. falciparum). Treatment group receives aPDT treatments, control group conventional ACT therapy. No m

5 treatments in total within 14 days. Follow up on day 28 after first treatment with both groups.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults aged 18 years and above with uncomplicated malaria from Ibadan, Nigeria and its environs.

Exclusion criteria

Exclusion criteria: 1. Age <18 years 2. Pregnancy

Design outcomes

Primary

Measure	Time frame
Parasite count on day 0, day 2, day 4, day 8, day 14 and day 28 by blood test	—

Secondary

Measure	Time frame
Safety measurements on day 0, day 2, day 4, day 8, day 14 and day 28 by blood test: 1. White blood cell count 2. Packed cell volume test (hematocrit)	—

Countries

Nigeria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026